Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Paraganglioma, Extra-Adrenal 2Neoplasms 2Glioma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Meningeal Carcinomatosis 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Medullary 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 8Irinotecan 7Melphalan 6Cyclophosphamide 6X-Rays 5Topotecan 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Granulocyte Colony-Stimulating Factor 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Busulfan 4palbociclib 3fludarabine 3Vincristine 3Thiotepa 3Stem Cell Transplantation 3Sirolimus 3Nivolumab 3Etoposide 3Bone Marrow Transplantation 3Biopsy 3ulixertinib 2tipifarnib 2thymoglobulin 2tazemetostat 2selpercatinib 2omburtamab I-131 2olaparib 2larotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × lenvatinib × CNS × Clear all
NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Eisai Inc.

Phase 1/2 Completed
64 enrolled 29 charts
CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡